Dr Bazhenova on Perioperative Treatment Selection in EGFR– or ALK-Mutated NSCLC
Lyudmila A. Bazhenova, MD, discusses factors to consider when navigating the use of neoadjuvant vs adjuvant EGFR– and ALK-directed treatment strategies for patients with non–small cell lung cancer who express oncogenic drivers.